nach oben

Wiener klinische Wochenschrift

Erschienen in:

12.06.2023 | original article

Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws

verfasst von: Shenghong Wu, Yu Wang, Jinfeng Zhang, Zhonghui He, Yuanjue Sun, Ming Ye

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2023

Einloggen, um Zugang zu erhalten

Summary

Background

Osteosarcoma of the jaw is one of the rare malignancies and the role of postoperative adjuvant therapy is unclear. This study explored the efficacy of adjuvant therapy after radical surgery for primary osteosarcoma of the jaw.

Methods

The data were retrospectively analyzed from May 2012 to June 2021. The recurrence rate, disease-free survival (DFS) and 5‑year overall survival (OS) rate were calculated by Kaplan-Meier method. Intergroup rates were examined by chi-square test.

Results

125 post-radical surgery patients were included. The median follow-up time was 66 months. Forty five cases suffered recurrence. The recurrence rate was 36.0%, and the 5‑year OS rate was 68.8%. In the adjuvant treatment group, twenty eight of 99 patients experienced disease progression. In the surgical treatment alone group, seventeen of 26 patients experienced disease progression. The recurrence rates in the two groups were 28.3 and 65.4%, respectively (χ² = 12.303, p < 0.001). The 5‑year OS rate was 75.8 and 42.3%, respectively (χ² = 10.734, p = 0.001). The median DFS of the relapse patients was 15.1 months (95% CI:13.00–17.20 months), and the 5‑year OS rate was 40.0%. Among them, 28 patients received adjuvant therapy while 17 received surgical treatment alone. The median DFS was 15.7 and 11.5 months, respectively, p = 0.024. The median OS was 69.6 months (95% CI 55.69 ~ 83.51 months) and 62.4 months (95% CI 49.06 ~ 75.74 months), respectively(p = 0.034).

Conclusion

Adjuvant therapy is one of the effective measures to reduce the relapse rate and improve OS after radical surgery for primary osteosarcoma of the jaw.

Vorheriger Artikel Primary tumor SUVmax and ratio of SUVmax to primary tumor size on pretreatment 18F-FDG-PET/CT scan in small cell lung cancer

Nächster Artikel The great mimicker of dural pathology: primary dural diffuse large B-cell lymphoma

Choi JH, Ro JY. The 2020 WHO classification of tumors of bone: an updated review. Adv Anat Pathol. 2021;28(3):119–38. https://doi.org/10.1097/PAP.0000000000000293.CrossRefPubMed

Clark JL, Unni KK, Dahlin DC, et al. Osteosarcoma of the jaw. Cancer. 1983;51(12):2311–6. https://doi.org/10.1002/1097-0142(19830615)51:12〈2311::aid-cncr2820511224〉3.0.co;2‑z. PMID: 6573939.CrossRefPubMed

Granowski-LeCornu M, Chuang SK, Kaban LB, et al. Osteosarcoma of the jaws: factors influencing prognosis. J Oral Maxillofac Surg. 2011;69(9):2368–75. https://doi.org/10.1016/j.joms.2010.10.023.CrossRefPubMed

Bennett JH, Thomas G, Evans AW, et al. Osteosarcoma of the jaws: a 30-year retrospective review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90(3):323–32. https://doi.org/10.1067/moe.2000.108274.CrossRefPubMed

Mardinger O, Givol N, Talmi YP, et al. Osteosarcoma of the jaw. The Chaim Sheba medical center experience. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(4):445–51. https://doi.org/10.1067/moe.2001.112330.CrossRefPubMed

Smith RB, Apostolakis LW, Karnell LH, et al. National Cancer Data Base report on osteosarcoma of the head and neck. Cancer. 2003;98(8):1670–80. https://doi.org/10.1002/cncr.11716.CrossRefPubMed

Kontio R, Hagström J, Lindholm P, et al. Craniomaxillofacial osteosarcoma—The role of surgical margins. J Craniomaxillofac Surg. 2019;47(6):922–5. https://doi.org/10.1016/j.jcms.2019.03.020.CrossRefPubMed

Ricotta F, Bassi M, Tomasetti N, et al. Osteosarcoma of the jaws: a literature review. Curr Med Imaging. 2021;17(2):225–35. https://doi.org/10.2174/1573405616666200806173948.CrossRefPubMed

Patel SG, Meyers P, Huvos AG, et al. Improved outcomes in patients with osteogenic sarcoma of the head and neck. Cancer. 2002;95(7):1495–503. https://doi.org/10.1002/cncr.10849.CrossRefPubMed

10.

van Es RJ, Keus RB, van der Waal I, et al. Osteosarcoma of the jaw bones. Long-term follow up of 48 cases. Int J Oral Maxillofac Surg. 1997;26(3):191–7. https://doi.org/10.1016/s0901-5027(97)80818-1.CrossRefPubMed

11.

Kämmerer PW, Shabazfar N, Vorkhshori Makoie N, et al. Clinical, therapeutic and prognostic features of osteosarcoma of the jaws—experience of 36 cases. J Craniomaxillofac Surg. 2012;40(6):541–8. https://doi.org/10.1016/j.jcms.2011.10.001.CrossRefPubMed

12.

Chindia ML. Osteosarcoma of the jaw bones. Oral Oncol. 2001;37(7):545–7. https://doi.org/10.1016/s1368-8375(00)00129-9.CrossRefPubMed

13.

Eder-Czembirek C, Moser D, Holawe S, et al. Osteosarcoma of the jaw—Experience at the Medical University Vienna and comparative study with international tumor registries. Clinics (Sao Paulo). 2019;74:e701. https://doi.org/10.6061/clinics/2019/e701.CrossRefPubMed

14.

Bertin H, Gomez-Brouchet A, Rédini F. Osteosarcoma of the jaws: An overview of the pathophysiological mechanisms. Crit Rev Oncol Hematol. 2020; https://doi.org/10.1016/j.critrevonc.2020.103126.CrossRefPubMed

15.

Slootweg PJ, Müller H. Osteosarcoma of the jaw bones. Analysis of 18 cases. J Maxillofac Surg. 1985;13(4):158–66. https://doi.org/10.1016/s0301-0503(85)80040-0.CrossRefPubMed

16.

Delgado R, Maafs E, Alfeiran A, et al. Osteosarcoma of the jaw. Head Neck. 1994;16(3):246–52. https://doi.org/10.1002/hed.2880160307.CrossRefPubMed

17.

Lee RJ, Arshi A, Schwartz HC, et al. Characteristics and prognostic factors of Osteosarcoma of the jaws: A retrospective cohort study. JAMA Otolaryngol Head Neck Surg. 2015;141(5):470–7. https://doi.org/10.1001/jamaoto.2015.0340.CrossRefPubMed

18.

Laskar S, Basu A, Muckaden MA, D’Cruz A, Pai S, Jambhekar N, Tike P, Shrivastava SK. Osteosarcoma of the head and neck region: lessons learned from a single-institution experience of 50 patients. Head Neck. 2008;30(8):1020–6. https://doi.org/10.1002/hed.20820.CrossRefPubMed

19.

Ferrari D, Codecà C, Battisti N, et al. Multimodality treatment of osteosarcoma of the jaw: a single institution experience. Med Oncol. 2014;31(9):171. https://doi.org/10.1007/s12032-014-0171-9.CrossRefPubMed

20.

Thariat J, Julieron M, Brouchet A, et al. Osteosarcomas of the mandible: are they different from other tumor sites? Crit Rev Oncol Hematol. 2012;82(3):280–95. https://doi.org/10.1016/j.critrevonc.2011.07.001.CrossRefPubMed

21.

Tanzawa H, Uchiyama S, Sato K. Statistical observation of osteosarcoma of the maxillofacial region in Japan. Analysis of 114 Japanese cases reported between 1930 and 1989. Oral Surg Oral Med Oral Pathol. 1991;72(4):444–8. https://doi.org/10.1016/0030-4220(91)90558-t.CrossRefPubMed

22.

Guadagnolo BA, Zagars GK, Raymond AK, et al. Osteosarcoma of the jaw/craniofacial region: outcomes after multimodality treatment. Cancer. 2009;115(14):3262–70. https://doi.org/10.1002/cncr.24297.CrossRefPubMed

23.

August M, Magennis P, Dewitt D. Osteogenic sarcoma of the jaws: factors influencing prognosis. Int J Oral Maxillofac Surg. 1997;26(3):198–204. https://doi.org/10.1016/s0901-5027(97)80819-3.CrossRefPubMed

24.

Steve M, Ernenwein D, Chaine A, et al. Ostéosarcomes des mâchoires [Jaw osteosarcomas]. Rev Stomatol Chir Maxillofac. 2011;112(5):286–92. https://doi.org/10.1016/j.stomax.2011.08.006.CrossRefPubMed

25.

Thariat J, Schouman T, Brouchet A, et al. Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE. Ann Oncol. 2013;24(3):824–31. https://doi.org/10.1093/annonc/mds507.CrossRefPubMed

26.

Paparella ML, Olvi LG, Brandizzi D, et al. Osteosarcoma of the jaw: an analysis of a series of 74 cases. Histopathology. 2013;63(4):551–7. https://doi.org/10.1111/his.12191.CrossRefPubMed

27.

Yoshida A. Osteosarcoma: old and new challenges. Surg Pathol Clin. 2021;14(4):567–83. https://doi.org/10.1016/j.path.2021.06.003.CrossRefPubMed

28.

Chui MH, Kandel RA, Wong M, et al. Histopathologic features of prognostic significance in high-grade osteosarcoma. Arch Pathol Lab Med. 2016;140(11):1231–42. https://doi.org/10.5858/arpa.2015-0389-OA.CrossRefPubMed

29.

Padilla RJ, Murrah VA. The spectrum of gnathic osteosarcoma: caveats for the clinician and the pathologist. Head Neck Pathol. 2011;5(1):92–9. https://doi.org/10.1007/s12105-010-0218-y.CrossRefPubMed

30.

Laskar S, Kakoti S, Khanna N, et al. Outcomes of osteosarcoma, chondrosarcoma and chordoma treated with image guided-intensity modulated radiation therapy. Radiother Oncol. 2021;164:216–22. https://doi.org/10.1016/j.radonc.2021.09.018.CrossRefPubMed

31.

Jingu K, Tsujii H, Mizoe JE, et al. Carbon ion radiation therapy improves the prognosis of unresectable adult bone and soft-tissue sarcoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012;82(5):2125–31. https://doi.org/10.1016/j.ijrobp.2010.08.043.CrossRefPubMed

32.

Hug EB, Fitzek MM, Liebsch NJ, et al. Locally challenging osteo- and chondrogenic tumors of the axial skeleton: results of combined proton and photon radiation therapy using three-dimensional treatment planning. Int J Radiat Oncol Biol Phys. 1995;31(3):467–76. https://doi.org/10.1016/0360-3016(94)00390-7.CrossRefPubMed

33.

Ha TW, Park S, Youn MY, et al. Carbon-ion radiotherapy in osteosarcoma of the mandible: a case report. J Korean Assoc Oral Maxillofac Surg. 2021;47(4):315–20. https://doi.org/10.5125/jkaoms.2021.47.4.315.CrossRefPubMedPubMedCentral

34.

Huang Q, Hu J, Hu W, et al. Comparison of the efficacy and toxicity of postoperative proton versus carbon ion radiotherapy for head and neck cancers. Ann Transl Med. 2022;10(22):1197. https://doi.org/10.21037/atm-20-5078.CrossRefPubMedPubMedCentral

35.

Seidensaal K, Mattke M, Haufe S, et al. The role of combined ion-beam radiotherapy (CIBRT) with protons and carbon ions in a multimodal treatment strategy of inoperable osteosarcoma. Radiother Oncol. 2021;159:8–16. https://doi.org/10.1016/j.radonc.2021.01.029.CrossRefPubMed

36.

Blattmann C, Oertel S, Schulz-Ertner D, et al. Non-randomized therapy trial to determine the safety and efficacy of heavy ion radiotherapy in patients with non-resectable osteosarcoma. BMC Cancer. 2010;10:96. https://doi.org/10.1186/1471-2407-10-96.CrossRefPubMedPubMedCentral

37.

Matsunobu A, Imai R, Kamada T, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118(18):4555–63. https://doi.org/10.1002/cncr.27451.CrossRefPubMed

38.

Ramaekers BL, Pijls-Johannesma M, Joore MA, et al. Systematic review and meta-analysis of radiotherapy in various head and neck cancers: comparing photons, carbon-ions and protons. Cancer Treat Rev. 2011;37(3):185–201. https://doi.org/10.1016/j.ctrv.2010.08.004.CrossRefPubMed

39.

Glanzmann C, Grätz KW. Radionecrosis of the mandibula: a retrospective analysis of the incidence and risk factors. Radiother Oncol. 1995;36(2):94–100. https://doi.org/10.1016/0167-8140(95)01583-3.CrossRefPubMed

40.

Studer G, Grätz KW, Glanzmann C. Osteoradionecrosis of the mandibula in patients treated with different fractionations. Strahlenther Onkol. 2004;180(4):233–40. https://doi.org/10.1007/s00066-004-1171-z.CrossRefPubMed

41.

Jereczek-Fossa BA, Orecchia R. Radiotherapy-induced mandibular bone complications. Cancer Treat Rev. 2002;28(1):65–74. https://doi.org/10.1053/ctrv.2002.0254.CrossRefPubMed

42.

Sasahara G, Koto M, Ikawa H, et al. Effects of the dose-volume relationship on and risk factors for maxillary osteoradionecrosis after carbon ion radiotherapy. Radiat Oncol. 2014;9(1):92. https://doi.org/10.1186/1748-717X-9-92.CrossRefPubMedPubMedCentral

Titel: Clinical significance of adjuvant therapy after radical surgery for primary osteosarcoma of the jaws
verfasst von: Shenghong Wu
Yu Wang
Jinfeng Zhang
Zhonghui He
Yuanjue Sun
Ming Ye
Publikationsdatum: 12.06.2023
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 17-18/2023
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-023-02228-x

Springer Medizin Österreich

Summary

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17-18/2023

Correction to: Screening for colorectal cancer

Billrothhaus: 130 Jahre Schauplatz der Medizingeschichte

Screening for colorectal cancer

Axillary lymph node status and invasive lobular breast cancer

The great mimicker of dural pathology: primary dural diffuse large B-cell lymphoma

MUW researcher of the month